Brain Inflammation Triggers Protective Neuropeptides PACAP and VIP as a Defense Response

GFAP-IL6 transgenic mice (with astrocyte-targeted IL-6 production) showed significantly increased transcripts and protein levels of both PACAP and VIP, plus their receptors PAC1, VPAC1, and VPAC2, in both cerebrum and cerebellum compared to wild-type littermates. This was accompanied by robust activation of JAK/STAT3, NF-κB, and ERK1/2MAPK signaling pathways. Blocking IL-6 trans-signaling (using sgp130Fc co-expression) reduced VIP expression and attenuated STAT3 and NF-κB activation, but failed to rescue PACAP levels, receptor expression, or ERK1/2MAPK phosphorylation — indicating PACAP induction involves trans-signaling-independent mechanisms.

Researchers used GFAP-IL6 transgenic mice with CNS-restricted, astrocyte-targeted IL-6 production, compared to wild-type littermates. Bi-genic GFAP-IL6/sgp130Fc mice were used to test whether blocking IL-6 trans-signaling would rescue neuropeptide changes. PACAP and VIP transcript and protein levels were measured in cerebrum and cerebellum, along with receptor expression and activation of JAK/STAT3, NF-κB, and ERK1/2MAPK signaling pathways using RT-qPCR, protein assays, and immunostaining.

Neuroinflammation is a common feature of Alzheimer's, Parkinson's, multiple sclerosis, and other brain diseases. Understanding that the brain has a built-in neuropeptide defense system that activates in response to inflammation could lead to new therapeutic strategies — potentially boosting PACAP and VIP levels to enhance the brain's natural protective response.

PACAP and VIP are increasingly recognized as endogenous neuroprotective agents. This study reveals they are part of a homeostatic brain defense system that activates in response to inflammation. If this response can be therapeutically enhanced, it could provide a new approach to treating neurodegenerative diseases where inflammation drives brain damage.

This was a transgenic mouse study with artificial IL-6 overexpression, which may not fully replicate the nuanced inflammatory processes in human neurodegenerative diseases. The forced IL-6 expression is constitutive and extreme, unlike the fluctuating inflammation seen in clinical conditions. The study did not assess whether the PACAP/VIP upregulation actually conferred neuroprotection in these mice. Behavioral and cognitive outcomes were not measured.